JP2022538237A5 - - Google Patents
Info
- Publication number
- JP2022538237A5 JP2022538237A5 JP2021576635A JP2021576635A JP2022538237A5 JP 2022538237 A5 JP2022538237 A5 JP 2022538237A5 JP 2021576635 A JP2021576635 A JP 2021576635A JP 2021576635 A JP2021576635 A JP 2021576635A JP 2022538237 A5 JP2022538237 A5 JP 2022538237A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025087586A JP2025138634A (ja) | 2019-06-24 | 2025-05-27 | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962865381P | 2019-06-24 | 2019-06-24 | |
| US62/865,381 | 2019-06-24 | ||
| US201962940589P | 2019-11-26 | 2019-11-26 | |
| US62/940,589 | 2019-11-26 | ||
| US202062967401P | 2020-01-29 | 2020-01-29 | |
| US62/967,401 | 2020-01-29 | ||
| US202063034106P | 2020-06-03 | 2020-06-03 | |
| US63/034,106 | 2020-06-03 | ||
| PCT/IB2020/055872 WO2020261093A1 (en) | 2019-06-24 | 2020-06-22 | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025087586A Division JP2025138634A (ja) | 2019-06-24 | 2025-05-27 | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538237A JP2022538237A (ja) | 2022-09-01 |
| JPWO2020261093A5 JPWO2020261093A5 (https=) | 2023-06-27 |
| JP2022538237A5 true JP2022538237A5 (https=) | 2023-06-27 |
Family
ID=71738213
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576635A Withdrawn JP2022538237A (ja) | 2019-06-24 | 2020-06-22 | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
| JP2025087586A Pending JP2025138634A (ja) | 2019-06-24 | 2025-05-27 | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025087586A Pending JP2025138634A (ja) | 2019-06-24 | 2025-05-27 | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220332821A1 (https=) |
| EP (1) | EP3986569A1 (https=) |
| JP (2) | JP2022538237A (https=) |
| KR (1) | KR20220024729A (https=) |
| CN (2) | CN119679936A (https=) |
| AU (1) | AU2020307471A1 (https=) |
| CA (1) | CA3144324A1 (https=) |
| IL (1) | IL289187A (https=) |
| TW (1) | TW202115114A (https=) |
| WO (1) | WO2020261093A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| EA201792573A1 (ru) | 2015-05-21 | 2018-04-30 | Харпун Терапьютикс, Инк. | Триспецифические связанные белки и способы их применения |
| JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| HRP20241268T1 (hr) | 2017-10-13 | 2024-12-06 | Harpoon Therapeutics, Inc. | Trispecifični proteini i postupci primjene |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| SG11202103022WA (en) | 2018-09-25 | 2021-04-29 | Harpoon Therapeutics Inc | Dll3 binding proteins and methods of use |
| EP3819007B1 (en) | 2019-11-11 | 2024-07-10 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
| CN116249548A (zh) | 2020-05-11 | 2023-06-09 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
| CA3182887A1 (en) * | 2020-05-13 | 2021-11-18 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
| CN116568707A (zh) * | 2021-01-29 | 2023-08-08 | 上海翰森生物医药科技有限公司 | 一种抗体药物偶联物及其医药用途 |
| CN119569887A (zh) * | 2021-06-24 | 2025-03-07 | 益科思特(北京)医药科技发展有限公司 | 结合bcma和cd3的双特异性抗体及其制备方法与应用 |
| TW202325743A (zh) * | 2021-07-14 | 2023-07-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｃｄ３８、ｂｃｍａ和ｃｄ３的抗原結合分子及其醫藥用途 |
| CN113908395B (zh) * | 2021-10-13 | 2024-05-17 | 科悦医疗(苏州)有限公司 | 一种促醒仪 |
| IL312503A (en) * | 2021-11-03 | 2024-07-01 | Janssen Biotech Inc | Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies |
| WO2025042742A1 (en) * | 2023-08-18 | 2025-02-27 | Bristol-Myers Squibb Company | Compositions comprising antibodies that bind bcma and cd3 and methods of treatment |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5942400A (en) | 1995-06-07 | 1999-08-24 | Elan Pharmaceuticals, Inc. | Assays for detecting β-secretase |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US7468365B2 (en) | 2000-11-17 | 2008-12-23 | Eli Lilly And Company | Lactam compound |
| GB0120347D0 (en) | 2001-08-21 | 2001-10-17 | Merck Sharp & Dohme | Therapeutic agents |
| KR100834177B1 (ko) | 2003-09-09 | 2008-05-30 | 에프. 호프만-라 로슈 아게 | 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체 |
| RU2364587C2 (ru) | 2003-10-29 | 2009-08-20 | Элан Фармасьютикалз, Инк. | N-замещенные бензолсульфонамиды |
| US20070161700A1 (en) | 2004-12-28 | 2007-07-12 | Kowa Company, Ltd. | Inhibitor for the formation of y-secretase complex |
| CN1934091B (zh) | 2004-03-23 | 2012-02-08 | 辉瑞产品公司 | 治疗神经变性障碍的咪唑化合物 |
| WO2007019232A2 (en) * | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| PE20080169A1 (es) | 2006-02-17 | 2008-04-11 | Wyeth Corp | Metodo para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios |
| WO2007129457A1 (ja) | 2006-04-25 | 2007-11-15 | The University Of Tokyo | アルツハイマー病および癌の治療薬 |
| EP2176233A1 (en) | 2007-08-07 | 2010-04-21 | Schering Corporation | Gamma secretase modulators |
| MX2010001754A (es) | 2007-08-14 | 2010-05-14 | Lilly Co Eli | Derivados de azepina como inhibidores de gamma secretasa. |
| US8084477B2 (en) | 2007-10-31 | 2011-12-27 | Bristol-Myers Squibb Company | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production |
| TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯二氮呯酮化合物 |
| WO2013066740A1 (en) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP2925313A4 (en) | 2012-11-29 | 2016-05-11 | Merck Sharp & Dohme | SPIROCYCLIC SULPHONES AS GAMMA SECRETASE INHIBITORS |
| WO2016075670A1 (en) * | 2014-11-14 | 2016-05-19 | Novartis Ag | Antibody drug conjugates |
| BR112017011166A2 (pt) * | 2014-11-26 | 2018-02-27 | Xencor, Inc. | anticorpos heterodiméricos que se ligam a cd3 e cd38 |
| CN110894240B (zh) * | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| PL3988117T3 (pl) | 2015-04-13 | 2025-03-10 | Pfizer Inc. | Przeciwciała terapeutyczne i ich zastosowania |
| AU2016297793A1 (en) | 2015-07-24 | 2018-02-08 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| EA201891732A1 (ru) * | 2016-02-02 | 2019-02-28 | Кадмон Корпорейшн, Ллк | Биспецифичные связывающие белки для pd-l1 и kdr |
| EP4295918A3 (en) * | 2016-11-02 | 2024-03-20 | Bristol-Myers Squibb Company | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| UY38251A (es) * | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
-
2020
- 2020-06-22 KR KR1020227001880A patent/KR20220024729A/ko not_active Withdrawn
- 2020-06-22 CN CN202411465492.1A patent/CN119679936A/zh active Pending
- 2020-06-22 US US17/620,987 patent/US20220332821A1/en active Pending
- 2020-06-22 EP EP20743802.9A patent/EP3986569A1/en active Pending
- 2020-06-22 WO PCT/IB2020/055872 patent/WO2020261093A1/en not_active Ceased
- 2020-06-22 CN CN202080059452.0A patent/CN114286828A/zh active Pending
- 2020-06-22 CA CA3144324A patent/CA3144324A1/en active Pending
- 2020-06-22 TW TW109121083A patent/TW202115114A/zh unknown
- 2020-06-22 JP JP2021576635A patent/JP2022538237A/ja not_active Withdrawn
- 2020-06-22 AU AU2020307471A patent/AU2020307471A1/en not_active Abandoned
-
2021
- 2021-12-20 IL IL289187A patent/IL289187A/en unknown
-
2025
- 2025-05-27 JP JP2025087586A patent/JP2025138634A/ja active Pending